About Quotient Limited
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic Substances
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: QTNT
- Previous Close: $6.40
- 50 Day Moving Average: $6.33
- 200 Day Moving Average: $6.05
- 52-Week Range: $3.75 - $12.96
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.57
- P/E Growth: 0.00
- Market Cap: $91.29M
- Outstanding Shares: 14,376,000
- Beta: 1.42
- Net Margins: -341.53%
- Return on Equity: -306.53%
- Return on Assets: -66.38%
Companies Related to Quotient Limited:
- Debt-to-Equity Ratio: -15.98%
- Current Ratio: 2.38%
- Quick Ratio: 1.87%
What is Quotient Limited's stock symbol?
Quotient Limited trades on the NASDAQ under the ticker symbol "QTNT."
Where is Quotient Limited's stock going? Where will Quotient Limited's stock price be in 2017?
1 equities research analysts have issued twelve-month price objectives for Quotient Limited's shares. Their predictions range from $16.00 to $16.00. On average, they anticipate Quotient Limited's share price to reach $16.00 in the next year.
When will Quotient Limited announce their earnings?
Quotient Limited is scheduled to release their next quarterly earnings announcement on Monday, May, 22nd 2017.
Who owns Quotient Limited stock?
Quotient Limited's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (19.86%), Alyeska Investment Group L.P. (4.19%) and Birchview Capital LP (0.40%). Company insiders that own Quotient Limited stock include D J Paul E Cowan, Jeremy Stackawitz, L John Wilkerson, Sarah A Oconnor, Stephen Unger and Zubeen Shroff.
Who sold Quotient Limited stock? Who is selling Quotient Limited stock?
Quotient Limited's stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P.. Company insiders that have sold Quotient Limited stock in the last year include Jeremy Stackawitz and Stephen Unger.
Who bought Quotient Limited stock? Who is buying Quotient Limited stock?
Quotient Limited's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought Quotient Limited stock in the last two years include D J Paul E Cowan, L John Wilkerson, Sarah A Oconnor, Stephen Unger and Zubeen Shroff.
How do I buy Quotient Limited stock?
Shares of Quotient Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Quotient Limited stock cost?
One share of Quotient Limited stock can currently be purchased for approximately $6.35.